Autoimmune diseases affect one in eight people, yet many are still treated by suppressing the entire immune system. But what if all of them shared a common root cause – a small number of rogue immune cells that could be identified and removed?

In this episode, Garvan's Professor Chris Goodnow explains how he's tracking down these 'rogue clones', and how targeting them could pave the way for more effective treatments for autoimmune diseases.

Autoimmune diseases affect one in eight people, yet many are still treated by suppressing the entire immune system. But what if all of them shared a common root cause &ndash; a small number of rogue immune cells that could be identified and removed?
In this episode, Garvan's Professor Chris Goodnow explains how he's tracking down these 'rogue clones', and how targeting them could pave the way for more effective treatments for autoimmune diseases.

Finding the needle in the haystack

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/31c48c6e-4a68-4682-b5f5-b4db01789436/transcript

Pancreatic cancer can surround itself with dense scar tissue, creating a kind of fortress that makes tumours incredibly difficult to treat. So, how do we find a way through?

In this episode, Garvan researcher Dr Brooke Pereira explains the role of this complex tumour environment, and reveals how better understanding it could be the key to uncovering new treatment options.

Pancreatic cancer can surround itself with dense scar tissue, creating a kind of fortress that makes tumours incredibly difficult to treat. So, how do we find a way through?
In this episode, Garvan researcher Dr Brooke Pereira explains the role of this complex tumour environment, and reveals&nbsp;how better understanding it could be the key to uncovering new treatment options.

Storming the tumour fortress 

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/93317ee4-2f5e-4964-8fad-b4bb005b3150/transcript

Our immune system is like a well-trained security network, constantly scanning the body for threats. So, how is it that some harmful cells manage to slip by unnoticed?

In this episode, we speak to computational biologist, Dr Clare Puttick, about how cancer cells can evade detection by disrupting the molecular “flags” that would normally mark them for attack.

Her research is uncovering new ways to expose these hidden cells and could offer fresh insights into diseases where the immune system doesn’t behave as expected, including endometriosis.

 

Our immune system is like a well-trained security network, constantly scanning the body for threats. So, how is it that some harmful cells manage to slip by unnoticed?
In this episode, we speak to computational biologist, Dr Clare Puttick, about how cancer cells can evade detection by disrupting the molecular &ldquo;flags&rdquo; that would normally mark them for attack.
Her research is uncovering new ways to expose these hidden cells and could offer fresh insights into diseases where the immune system doesn&rsquo;t behave as expected, including endometriosis.
&nbsp;

Hunting hidden cells

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/a936857b-b908-45b7-a925-b46c017bc1e2/transcript

What if the missing piece in diagnosing, and even treating, a rare disease was hiding in plain sight? For one such condition, mevalonate kinase deficiency, which affects at least one in a million people globally, that piece may now have been uncovered.

In this episode, Garvan's Professor Mike Rogers shares insights from more than a decade of research into this condition, and explains how his findings are helping reveal a bigger picture.

What if the missing piece in diagnosing, and even treating, a rare disease was hiding in plain sight? For one such condition, mevalonate kinase deficiency, which affects at least one in a million people globally, that piece may now have been uncovered.
In this episode, Garvan's Professor Mike Rogers shares insights from more than a decade of research into this condition, and explains how his findings are helping reveal a bigger picture.

The missing piece of the puzzle

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/03c7fe37-f422-4711-be8b-b42d000d35d5/transcript

Immunotherapy has revolutionised the treatment of many blood cancers, harnessing the immune system so our bodies can fight back. But for solid tumours, like pancreatic cancer with a survival rate of just 13%, that breakthrough has remained frustratingly out of reach. 

In this episode, we explore why the immune system struggles to attack these tumours and how the physical environment inside cancers can shape the way immune cells behave.

We hear from Garvan's Associate Professor Maté Biro, whose research maps how cells move inside of tumours, with the goal of uncovering new strategies to improve cancer treatment.

Immunotherapy has revolutionised the treatment of many blood cancers, harnessing the immune system so our bodies can fight back. But for solid tumours, like pancreatic cancer with a survival rate of just 13%, that breakthrough has remained frustratingly out of reach.&nbsp;
In this episode, we explore why the immune system struggles to attack these tumours and how the physical environment inside cancers can shape the way immune cells behave.
We hear from Garvan's Associate Professor Mat&eacute; Biro, whose research maps how cells move inside of tumours, with the goal of uncovering new strategies to improve cancer treatment.

Calling killer cells to action

Arthritis affects millions of people, but the underlying causes are still not fully understood. What makes the immune system that normally protects us suddenly attack our joints? And why do arthritis flares seem to arrive without warning?

In this episode, we explore how certain immune cells or signals might be responsible for switching inflammation on.

We hear from Garvan's Dr Etienne Masle-Farquhar, who is mapping these processes in both rheumatoid arthritis and osteoarthritis, with the goal of predicting flares earlier and guiding more effective treatment.

Arthritis affects millions of people, but the underlying causes are still not fully understood. What makes the immune system that normally protects us suddenly attack our joints? And why do arthritis flares seem to arrive without warning?
In this episode, we explore how certain immune cells or signals might be responsible for switching inflammation on.
We hear from Garvan's Dr Etienne Masle-Farquhar, who is mapping these processes in both rheumatoid arthritis and osteoarthritis, with the goal of predicting flares earlier and guiding more effective treatment.

Arthritis: uncovering pathways to better treatment   

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/693e3518-8816-44e3-b70f-b3b00147ab9f/transcript

For decades, the fight against cancer has focused on killing the tumour cell. We treated cancer like an isolated entity that needed to be destroyed – but what if we’ve been looking at the wrong target?

In this episode, we delve into the critical insight that cancer is not just a rogue cell – it’s an entire ecosystem – and that ecosystem is the key to unlocking a new class of cures.

We hear from Garvan's Dr Ankur Sharma, who is using precision technology to dissect how the environment around liver cancers allows them to grow unchecked. The ultimate goal for this research is to develop better diagnostics and treatments for this deadly cancer.

For decades, the fight against cancer has focused on killing the tumour cell. We treated cancer like an isolated entity that needed to be destroyed &ndash; but what if we&rsquo;ve been looking at the wrong target?
In this episode, we delve into the critical insight that cancer is not just a rogue cell &ndash; it&rsquo;s an entire ecosystem &ndash; and that ecosystem is the key to unlocking a new class of cures.
We hear from Garvan's Dr Ankur Sharma, who is using precision technology to dissect how the environment around liver cancers allows them to grow unchecked. The ultimate goal for this research is to develop better diagnostics and treatments for this deadly cancer.

Liver cancer: discovering the next generation of therapy targets

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/e8a23dde-e99f-4d93-8323-b38d0189a6fd/transcript

Therapies and drugs have evolved enormously in the last 30 years. For example, in cancer, where previously our options were limited to surgery, chemotherapy and radiotherapy, we’re now hearing terms like cancer immunotherapy, targeted therapies and even cancer vaccines. Many of these are biologics.

In this episode you’ll hear from Dr Rachel Galimidi who is at the forefront of biologics drug development and is working to make new and better treatments for a range of diseases.

Therapies and drugs have evolved enormously in the last 30 years. For example, in cancer, where previously our options were limited to surgery, chemotherapy and radiotherapy, we&rsquo;re now hearing terms like cancer immunotherapy, targeted therapies and even cancer vaccines. Many of these are biologics.
In this episode you&rsquo;ll hear from Dr Rachel Galimidi who is at the forefront of biologics drug development and is working to make new and better treatments for a range of diseases.

Biologics- engineering tomorrow’s medicines

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/e1505154-eba4-47f6-b2a2-b37e00444206/transcript

Pancreatic cancer is one of the toughest cancers to treat – it’s aggressive, often diagnosed late, and doesn’t respond well to standard therapies. In this episode, we meet Professor Marina Pajic who is working at the cutting-edge of science to transform how we understand and treat this disease.

Pancreatic cancer is one of the toughest cancers to treat &ndash; it&rsquo;s aggressive, often diagnosed late, and doesn&rsquo;t respond well to standard therapies. In this episode, we meet Professor Marina Pajic who is working at the cutting-edge of science to transform how we understand and treat this disease.

Breaking the barriers to treating pancreatic cancer

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/2f51a968-9879-439c-9997-b2e70019c89b/transcript

Garvan is one of Australia's largest independent medical research institutes with a single focus: to make discoveries that will improve health for all. In this episode, you’ll hear from Executive Director Professor Benjamin Kile on how he came to be at Garvan's helm and his strategy for driving extraordinary science that will have transformational impact for patient lives.

Garvan is one of Australia's largest independent medical research institutes with a single focus: to make discoveries that will improve health for all. In this episode, you&rsquo;ll hear from Executive Director Professor Benjamin Kile on how he came to be at Garvan's helm and his strategy for driving extraordinary science that will have transformational impact for patient lives.

Accelerating discovery, empowering translation

https://api.omny.fm/orgs/acbb53f8-dca0-419a-b44f-af49001056ab/clips/d0192aaf-8a9d-4382-b553-b280017f93a1/transcript

We dive deep into the minds of our amazing researchers to find out how they tick and how they are working to make our lives better.

We dive deep into the minds of our amazing researchers to find out how they tick and how they are working to make our lives better.

Medical Minds

Social links:

Follow the podcast:

38 clip(s)